HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Zoster vaccine to prevent postherpetic neuralgia.

Abstract
In 2006, the U.S. Food and Drug Administration approved the first vaccine for the prevention of acute herpes zoster neuralgia (shingles). This vaccine has important implications in reducing the incidence and severity of the common neuropathic pain condition postherpetic neuralgia. The new vaccine is described.
AuthorsBenson Sederholm, David Peterson
JournalJournal of pain & palliative care pharmacotherapy (J Pain Palliat Care Pharmacother) Vol. 20 Issue 4 Pg. 41-2 ( 2006) ISSN: 1536-0288 [Print] England
PMID17182505 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Herpes Zoster Vaccine
Topics
  • Aged
  • Aged, 80 and over
  • Double-Blind Method
  • Drug Approval
  • Herpes Zoster (prevention & control)
  • Herpes Zoster Vaccine
  • Humans
  • Middle Aged
  • United States
  • United States Food and Drug Administration

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: